タイトル（掲載誌）令和1(2019)年度 科学研究費補助金 若手研究 研究概要 = 2019 Research Project Summary
一般注記Studies in vitro and in animal model were carried out complementary to optimize treatment of glioblastoma (GBM) by enhancing anti-tumor effect by combination of GSK3β inhibition and temozolomide (TMZ). For in vitro study, we examined effect of GSK3β inhibition and TMZ on patient derived GBM stem-like cells (SCs). I found that GSK3β inhibition enhances effect of TMZ against GBM-SCs and participate in regulation of GBM stemness phenotype. For animal model study, I have developed software pharmacokinetics model and determined optimal concentration of GSK3β inhibitor for continuous intra-tumor infusion by subcutaneous pumps for treatment of orthotopic GBM models and examined the effects of continuous intra-tumor infusion of GSK3β inhibitor, against GBM in mice bearing human GBM-SCs. Our experiments showed that GSK3β inhibition is effective for treatment of experimental GBM generated by inoculation of most malignant GBM-SCs characterized by shortest survival in control animals. We investigated biological mechanisms by which GSK3β regulate GBM stemness phenotype and revealed changes in stem cell markers’ expression in GBM-SCs under GSK3β inhibition, which can be associated with regulation of GBM stemness phenotype by GSK3β via multiple signaling pathways.
研究課題/領域番号:18K16553, 研究期間(年度):2018-04-01 - 2020-03-31
出典：「Investigation of putative roles for GSK3b in glioblastoma stemness phenotype and the underlying biological mechanisms」研究成果報告書 課題番号18K16553（KAKEN：科学研究費助成事業データベース（国立情報学研究所）） （https://kaken.nii.ac.jp/en/grant/KAKENHI-PROJECT-18K16553/）を加工して作成
関連情報https://kaken.nii.ac.jp/search/?qm=00731853
https://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-18K16553/
連携機関・データベース国立情報学研究所 : 学術機関リポジトリデータベース（IRDB）（機関リポジトリ）